132 related articles for article (PubMed ID: 37036671)
1. AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Suh KJ; Ryu MH; Zang DY; Bae WK; Lee HS; Oh HJ; Kang M; Kim JW; Kim BJ; Mortimer PGS; Kim HJ; Lee KW
Oncologist; 2023 Sep; 28(9):e823-e834. PubMed ID: 37036671
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Choudhury AD; Higano CS; de Bono JS; Cook N; Rathkopf DE; Wisinski KB; Martin-Liberal J; Linch M; Heath EI; Baird RD; García-Carbacho J; Quintela-Fandino M; Barry ST; de Bruin EC; Colebrook S; Hawkins G; Klinowska T; Maroj B; Moorthy G; Mortimer PG; Moschetta M; Nikolaou M; Sainsbury L; Shapiro GI; Siu LL; Hansen AR
Clin Cancer Res; 2022 Jun; 28(11):2257-2269. PubMed ID: 35247924
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
4. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Smyth LM; Monson KR; Jhaveri K; Drilon A; Li BT; Abida W; Iyer G; Gerecitano JF; Gounder M; Harding JJ; Voss MH; Makker V; Ho AL; Razavi P; Iasonos A; Bialer P; Lacouture ME; Teitcher JB; Erinjeri JP; Katabi N; Fury MG; Hyman DM
Invest New Drugs; 2017 Dec; 35(6):742-750. PubMed ID: 28281183
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
Owusu-Brackett N; Zhao M; Akcakanat A; Evans KW; Yuca E; Dumbrava EI; Janku F; Meric-Bernstam F
Oncotarget; 2020 Mar; 11(11):969-981. PubMed ID: 32215185
[No Abstract] [Full Text] [Related]
6. Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma.
Moy RH; Greally M; Chou JF; Li J; Desai AM; Chalasani SB; Won E; Kelsen DP; Ilson DH; Janjigian YY; Capanu M; Ku GY
Cancer Chemother Pharmacol; 2022 Feb; 89(2):255-265. PubMed ID: 35066693
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Lynch JT; Polanska UM; Delpuech O; Hancox U; Trinidad AG; Michopoulos F; Lenaghan C; McEwen R; Bradford J; Polanski R; Ellston R; Avivar-Valderas A; Pilling J; Staniszewska A; Cumberbatch M; Critchlow SE; Cruzalegui F; Barry ST
Clin Cancer Res; 2017 Dec; 23(24):7584-7595. PubMed ID: 28972046
[No Abstract] [Full Text] [Related]
8. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study.
Lee CK; Lee JB; Park SJ; Che J; Kwon WS; Kim HS; Jung M; Lee S; Park SR; Koo DH; Lee HW; Bae WK; Jeung HC; Hwang IG; Kim H; Nam CM; Chung HC; Rha SY
Gastric Cancer; 2024 Jan; 27(1):118-130. PubMed ID: 37906316
[TBL] [Abstract][Full Text] [Related]
11. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
Ma WW; Li JJ; Azad NS; Lam ET; Diamond JR; Dy GK; Opyrchal M; Zhi J; Kramer D; Chan WK; Cutler D; Kwan R; Adjei AA; Jimeno A
Cancer Chemother Pharmacol; 2022 Jul; 90(1):7-17. PubMed ID: 35731258
[TBL] [Abstract][Full Text] [Related]
12. Correction to: AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Oncologist; 2024 Apr; 29(4):e579. PubMed ID: 37815173
[No Abstract] [Full Text] [Related]
13. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer.
Strickler JH; Rushing CN; Niedzwiecki D; McLeod A; Altomare I; Uronis HE; Hsu SD; Zafar SY; Morse MA; Chang DZ; Wells JL; Blackwell KL; Marcom PK; Arrowood C; Bolch E; Haley S; Rangwala FA; Hatch AJ; Nixon AB; Hurwitz HI
BMC Cancer; 2019 Nov; 19(1):1032. PubMed ID: 31675952
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.
Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W
Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.
Ryu MH; Ryoo BY; Kim TW; Kim SB; Lim HS; Bae KS; Park SR; Jo YW; Cho HJ; Kang YK
Oncologist; 2017 Feb; 22(2):129-e8. PubMed ID: 28196905
[TBL] [Abstract][Full Text] [Related]
17. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.
Von Hoff DD; Rasco DW; Heath EI; Munster PN; Schellens JHM; Isambert N; Le Tourneau C; O'Neil B; Mathijssen RHJ; Lopez-Martin JA; Edenfield WJ; Martin M; LoRusso PM; Bray GL; DiMartino J; Nguyen A; Liu K; Laille E; Bendell JC
Clin Cancer Res; 2018 Sep; 24(17):4072-4080. PubMed ID: 29764853
[No Abstract] [Full Text] [Related]
18. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
Kim CG; Jung M; Kim HS; Lee CK; Jeung HC; Koo DH; Bae WK; Zang DY; Kim BJ; Kim H; Yun UJ; Che J; Park S; Kim TS; Kwon WS; Park J; Cho SW; Nam CM; Chung HC; Rha SY
J Clin Oncol; 2023 Sep; 41(27):4394-4405. PubMed ID: 37364218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
